GlassScriptPhysician profile
Robin M Anderson
NPI 1780012245
$332,610.57
in general payments reported to CMS, 2019-2025
51 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24K · 2022: $47K · 2023: $109K · 2024: $82K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $186K · Travel and Lodging: $50K · Food and Beverage: $15K · Honoraria: $11K · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $185,955.00 |
| Travel and Lodging | $49,558.41 |
| Food and Beverage | $14,545.90 |
| Honoraria | $11,375.00 |
| Education | $116.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $319,145.44 | 2021-2025 | Korlym |
| Abbvie INC. | $2,777.06 | 2021-2025 | |
| Novo Nordisk INC | $1,165.67 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $1,132.74 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $1,100.56 | 2021-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $988.05 | 2021-2025 | Repatha, Repatha |
| Pfizer INC. | $415.51 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $365.49 | 2021-2025 | |
| Esperion Therapeutics, INC. | $358.13 | 2021-2025 | Nexletol |
| Eusa Pharma (US) LLC | $318.13 | 2022 | |
| Antares Pharma, INC. | $315.63 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Ibsa Pharma INC. | $303.45 | 2021-2024 | Tirosint, Licart, Licart |
| Lilly USA, LLC | $296.91 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $250.02 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $241.16 | 2021-2025 | Airsupra, Farxiga |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $236.40 | 2021-2025 | Trintellix |
| Astellas Pharma US INC | $224.90 | 2023-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $201.67 | 2022 | |
| Ironwood Pharmaceuticals, INC | $200.22 | 2021-2024 | Linzess |
| Axsome Therapeutics, INC. | $192.69 | 2023-2025 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.48 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Mannkind Corporation | $187.71 | 2021-2023 | Afrezza |
| Insulet Corporation | $173.83 | 2021-2024 | Omnipod |
| Aimmune Therapeutics, INC. | $160.29 | 2024-2025 | Zenpep |
| Supernus Pharmaceuticals, INC. | $153.75 | 2024 | Qelbree, Tlando, Xyosted |
| Ardelyx, INC. | $147.45 | 2022-2024 | Ibsrela |
| Bausch Health US, LLC | $142.46 | 2021-2025 | Aplenzin, Wellbutrin |
| Xeris Pharmaceuticals, INC. | $124.19 | 2021-2024 | Gvoke Hypopen |
| Abbott Laboratories | $117.32 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Lundbeck LLC | $116.33 | 2021-2024 | Vyepti, Rexulti |
| Dexcom, INC. | $110.13 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $75.36 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $74.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.18 | 2023-2025 | Jardiance, Synjardy |
| Otsuka America Pharmaceutical, INC. | $61.66 | 2022-2025 | Rexulti |
| Grt US Holding, INC. | $60.22 | 2022 | |
| Exeltis, USA INC. | $52.44 | 2023-2024 | Slynd |
| Halozyme INC | $38.48 | 2023 | |
| Tris Pharma INC | $36.34 | 2024 | Dyanavel Xr |
| Alkermes, INC. | $35.21 | 2022 | |
| Aurinia Pharma U.S., INC. | $35.07 | 2024 | Lupkynis |
| Exact Sciences Corporation | $33.93 | 2024 | Cologuard Collection Kit |
| Averitas Pharma INC. | $31.59 | 2024 | Qutenza |
| Azurity Pharmaceuticals, INC. | $31.47 | 2023 | Adthyza |
| Amneal Pharmaceuticals LLC | $21.66 | 2025 | Unithroid |
| Idorsia Pharmaceuticals US INC | $18.72 | 2023 | Quviviq |
| Vanda Pharmaceuticals INC. | $18.42 | 2025 | Fanapt |
| Amarin Pharma, INC. | $17.97 | 2022 | |
| Amag Pharmaceuticals, INC. | $16.91 | 2021 | |
| Glaxosmithkline, LLC. | $15.47 | 2024 | Benlysta |
| Philips North America LLC | $13.62 | 2025 | Patient Interface Software |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.